Celgene resubmits MS drug, ozanimod, to FDA by Anna Smith | Mar 27, 2019 | News | 0 A filing for ozanimod was initially rejected by the US regulator in February 2017. Read More
FDA turns away filing for Celgene’s MS drug by Selina McKee | Mar 1, 2018 | News | 0 US regulators are refusing to file Celgene’s application to market its experimental multiple sclerosis therapy ozanimod. Read More